This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Study Commissioned By CVS Caremark Highlights Opportunities To Significantly Reduce Spending On Costly Specialty Medications

WOONSOCKET, R.I., April 9, 2014 /PRNewswire/ -- Specialty medications present a challenge for payers as costs for these expensive drugs consume an increasing portion of overall health care spending. In fact, specialty pharmacy spend is expected to rise from $92 billion in 2012 to $235 billion by 2018. According to a new Milliman report commissioned by CVS Caremark, implementing an effective "channel transition" approach – the process of moving prescriptions from the medical benefit to the pharmacy benefit – can produce significant savings for health care payers by improving management of these complex and costly drugs.  
CVS Caremark logo

The report finds the transition from the medical to the pharmacy benefit can save payers an average of 19 percent across 14 classes of self- or provider-administered injectable specialty drugs for the treatment of conditions such as multiple sclerosis and autoimmune disorders.  By moving coverage to the pharmacy benefit, payers are able to implement more effective management tools such as formulary design, utilization management, and preferred or exclusive networks.  According to the report, more than half (53 percent) of specialty medication spending currently occurs under the medical benefit.

"With the continued rise in utilization and spend related to specialty medications, health care payers have a tremendous opportunity to reduce costs and improve care through a variety of approaches," said Alan Lotvin, M.D., executive vice president of Specialty Pharmacy for CVS Caremark.  "Transitioning specialty medications from the medical benefit to the pharmacy benefit, as well as offering patients more convenient options by addressing where infusion care is administered, can produce significant savings.  We are focused on finding ways to better manage the rising costs related to these complex and expensive drugs, while ensuring patients continue to receive high-quality care."

Compared to the average patient, specialty patients are more likely to have multiple diagnoses, see more specialists, fill more prescriptions and have more lab tests, ER visits and hospitalizations, resulting in overall health care costs as much as 8.5 times higher than non-specialty patients 1.

"CVS Caremark provides an end-to-end pharmacy management and delivery solution for specialty pharmacy patients that helps them better manage their medications and their disease throughout their journey," said Jon Roberts, president, CVS Caremark pharmacy benefit management business. "Our suite of programs focuses on managing cost, quality and access for specialty conditions through a range of unique specialty pharmacy services."

The CVS Caremark suite of specialty pharmacy services includes:
  • Industry-leading experience and proven outcomes related to managing across the medical and pharmacy benefit.
  • Team of specialized pharmacists, nurses and dieticians who manage the whole patient and support them throughout the progression of their disease to help control overall health care costs.
  • Unmatched, convenient access to specialty drugs, patient counseling and the appropriate site of care, combined with consistent clinical quality, improves the patient experience and adherence to their plan of care.

Access the full Milliman report at:

The study was based on 2012 claims data for a commercially insured population as reported in Milliman's Consolidated Health Cost Guidelines (HCG) database.  The study included plans with a variety of commercial plan designs (e.g., PPO, HMO and POS).

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $95.18 1.64%
FB $117.43 -0.96%
GOOG $692.36 -0.84%
TSLA $232.32 -3.92%
YHOO $36.01 -1.42%


Chart of I:DJI
DOW 17,750.91 -140.25 -0.78%
S&P 500 2,063.37 -18.06 -0.87%
NASDAQ 4,763.2240 -54.37 -1.13%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs